ScholarDeck

Cohort studyOcular immunology and inflammation · 2026

Fluocinolone Acetonide Versus Dexamethasone Intravitreal Implants for Non-Infectious Posterior-Segment Uveitis: 12-Month Real-World Outcomes.

Cong Chen, Wen-Jing Zhang, Shu-Min Shen … Yan-Ping Song

OphthalmologyCohort study

Fluocinolone implant linked to far fewer uveitis recurrences than dexamethasone implant.

Fluocinolone Acetonide Versus Dexamethasone Intravitreal Implants for Non-Infectious Posterior-Segment Uveitis: 12-Month Real-World Outcomes.

Cong Chen … Yan-Ping Song

Ocular immunology and inflammation · 2026

Purpose

To compare 12-month real-world outcomes and safety profiles of the fluocinolone acetonide intravitreal implant (FAi) versus the dexamethasone intravitreal implant (DEX) in non-infectious posterior-segment uveitis.

Methods

Single-center retrospective cohort study of eyes treated with FAi or DEX and followed for ≥12 months.

n = 117 eyes

Results

far fewer eyes had uveitis flare up again with fluocinolone than dexamethasone

13.2%

FAi

51.6%

DEX

More results

Both groups showed significant improvements in BCVA, central macular thickness, and subfoveal choroidal thickness from baseline.

At 6 and 12 months, central macular thickness was lower with FAi than with DEX ( p = 0.010 and p = 0.003), and subfoveal choroidal thickness was lower at 6 months ( p = 0.011), consistent with more sustained anatomical control.

More results

DEX showed greater BCVA improvement at 1 month ( p = 0.047); from months 3-12, visual outcomes were comparable.

IOP elevation and the need for laser or incisional surgery were greater with FAi.

“

Conclusion · 1 of 3

In this real-world cohort, both FAi and DEX provided clinically meaningful benefits, displaying complementary rather than competing profiles.

Conclusion · 2 of 3

FAi was associated with more sustained anatomical control and fewer injections but greater IOP management requirements, whereas DEX offered more rapid early visual improvement and a more favorable IOP profile.

Conclusion · 3 of 3

These hypothesis-generating findings support individualized implant selection and require prospective validation.

Fluocinolone Acetonide Versus Dexamethasone Intravitreal Implants for Non-Infectious Posterior-Segment Uveitis: 12-Month Real-World Outcomes.

Related papers